• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

  • HEK293 expressed
  • Endotoxin-free
  • Animal-component free

HumanKine® recombinant human IGF-I protein

Activity

2-14 ng/mL

Specific Activity

minimally 3.00 x 102 IU/mg

Species Reactivity

human

Purity

>95%

Cat no : HZ-1322

Synonyms

H-IGF-1, IGF, IGF-I, IGF-IA, IGF-IB, IGF1A, IGFIa, Insulin like growth factor, insulin-like growth factor 1 (somatomedin C), Insulin-like growth factor I, insulin-like growth factor IB, M-IGF-1, Mechano growth factor, MGF, OTTHUMP00000195084, R-IGF-1, Somatomedin C, Somatomedin-C

Validation Data Gallery

  • Purity of recombinant human IGF-I was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

    Purity of recombinant human IGF-I was determined by SDS- polyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

  • Recombinant human IGF-I (Cat no: HZ-1322) stimulates dose-dependent proliferation of the MCF-7 human breast cancer cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. MCF-7 cells were treated with increasing concentrations of recombinant IGF-I for 96 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-14 ng/mL.

    Recombinant human IGF-I (Cat no: HZ-1322) stimulates dose-dependent proliferation of the MCF-7 human breast cancer cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. MCF-7 cells were treated with increasing concentrations of recombinant IGF-I for 96 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-14 ng/mL.

  • Proteintech IGF-I (Cat no: HZ-1322) demonstrates equivalent fold induction and a 2-fold decrease in EC50 compared to leading competitors. Recombinant human IGF-I stimulates dose-dependent proliferation of the MCF-7 human breast cancer cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. MCF-7 cells were treated with increasing concentrations of recombinant IGF-I for 96 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-14 ng/mL.

    Proteintech IGF-I (Cat no: HZ-1322) demonstrates equivalent fold induction and a 2-fold decrease in EC50 compared to leading competitors. Recombinant human IGF-I stimulates dose-dependent proliferation of the MCF-7 human breast cancer cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. MCF-7 cells were treated with increasing concentrations of recombinant IGF-I for 96 hours. The EC50 was determined using a 4-parameter non-linear regression model. The EC50 range is 2-14 ng/mL.

Technical Specifications

GeneID 3479
Species Human
Expression HEK293
Activity 2-14 ng/mL
Specific Activityminimally 3.00 x 102 IU/mg
Purity >95%
Endotoxin<1 EU/µg
Accession NumberP05019
Molecular Mass 9-10 kDa reduced and non-reduced, monomer, non-glycosylated
Formulation 50mM Acetate pH 4.0
Species Reactivity human

Stability and Reconstitution

Stability and Storage Lyophilized proteins are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.
Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1x PBS pH 7.4 containing 0.1% endotoxin-free recombinant human serum albumin (HSA). Gently swirl or tap vial to mix.

Background

The Insulin like growth factor-1, also known as Somatomedin-C is a growth factor which is structurally related to insulin and is an important regulator of growth and differentiation in various tissues and cell systems. Human IGF-1 is synthesized as two precursor isoforms with N- and alternate C-terminal propeptide. The two precursor isoforms are differentially expressed by various tissues. The proteolytic cleavage of the N- and C-terminal regions results in the mature IGF-1 protein which is identical between isoforms. IGF-1 binds to IGF-1 receptor and induces receptor autophosphorylation. This further phosphorylates Insulin receptor substrate -1 (IRS-1) and activates various downstream signaling pathways including the PI3-AKT, MAPK etc. (PMID: 17354613, 17113337, 29535161)

Synonyms

H-IGF-1, IGF, IGF-I, IGF-IA, IGF-IB, IGF1A, IGFIa, Insulin like growth factor, insulin-like growth factor 1 (somatomedin C), Insulin-like growth factor I, insulin-like growth factor IB, M-IGF-1, Mechano growth factor, MGF, OTTHUMP00000195084, R-IGF-1, Somatomedin C, Somatomedin-C

Publications

SpeciesTitle
mouse

Sci Adv

Varying mechanical forces drive sensory epithelium formation

Authors - Mingyu Xia
View Article
human

Front Bioeng Biotechnol

Unveiling the mechanism of photothermal therapy in acne man-agement: targeting sebaceous gland ferroptosis via umbilical cord mesenchymal stem cell membrane-encapsulated Au-Ag-PDA

Authors - Ronghui Wu
View Article
human

Adv Sci (Weinh)

Integration of Functional Human Auditory Neural Circuits Based on a 3D Carbon Nanotube System

Authors - Yiyun Lou
View Article

ACS Biomater Sci Eng

Electrospun PCL Nerve Conduit Filled with GelMA Gel for CNTF and IGF-1 Delivery in Promoting Sciatic Nerve Regeneration in Rat

Authors - Hailiang Xu
View Article